Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor

Pigment Cell and Melanoma Research

Volumn 27, Issue 4, 2014, Pages 621-629

  Teh, Jessica L F ^a   Shah, Raj ^a   Shin, Seung Shick ^b,c   Wen, Yu ^b,c   Mehnert, Janice M ^b,c   Goydos, James ^b,c   Chen, Suzie ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Glutamate signaling; Grm1; IGF 1R; Melanoma; Transactivation

Indexed keywords

METABOTROPIC RECEPTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; AKT2 PROTEIN, MOUSE; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SIZE; CELL CLONE; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REPRESSION; EXPERIMENTAL MELANOMA; GENE DISRUPTION; GENE REPRESSION; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TRANSACTIVATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL LINE; GENETICS; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; INSULIN-LIKE GROWTH FACTOR I; MELANOCYTES; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTORS, METABOTROPIC GLUTAMATE; TRANSCRIPTIONAL ACTIVATION;

EID: 84902536833     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12237     Document Type: Article

References (37)

1. Almendro, V., Garcia-Recio, S., and Gascon, P. (2010). Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr. Drug Targets 11, 1169-1180.
2. Bhola, N.E., and Grandis, J.R. (2008). Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front. Biosci. 13, 1857-1865.
3. Chen, S., Zhu, H., Wetzel, W.J., and Philbert, M.A. (1996). Spontaneous melanocytosis in transgenic mice. J. Invest. Dermatol. 106, 1145-1151.
4. Choi, K.Y., Chang, K., Pickel, J.M., Badger, J.D. 2nd, and Roche, K.W. (2011). Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc. Natl Acad. Sci. U. S. A. 108, 15219-15224.
5. Cohen-Solal, K.A., Crespo-Carbone, S.M., Namkoong, J., Mackason, K.R., Roberts, K.G., Reuhl, K.R., and Chen, S. (2002). Progressive appearance of pigmentation in amelanotic melanoma lesions. Pigment Cell Res. 15, 282-289.
6. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
7. Delcourt, N., Bockaert, J., and Marin, P. (2007). GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol. Sci. 28, 602-607.
8. Esseltine, J.L., Willard, M.D., Wulur, I.H., Lajiness, M.E., Barber, T.D., and Ferguson, S.S. (2013). Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling. Mol. Pharmacol. 83, 770-780.
9. Fassnacht, M., Libe, R., Kroiss, M., and Allolio, B. (2011). Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 7, 323-335.
10. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
11. Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A.N., Busam, K., and Polsky, D. (2003). Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 63, 3955-3957.
12. Kanter-Lewensohn, L., Dricu, A., Girnita, L., Wejde, J., and Larsson, O. (2000). Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 17, 193-202.
13. Kim, W.Y., Prudkin, L., Feng, L. et al. (2012). Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 118, 3993-4003.
14. Lee, H.J., Wall, B.A., Wangari-Talbot, J., Shin, S.S., Rosenberg, S., Chan, J.L., Namkoong, J., Goydos, J.S., and Chen, S. (2011). Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin. Cancer Res. 17, 7080-7092.
15. Luttrell, D.K., and Luttrell, L.M. (2004). Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene 23, 7969-7978.
16. Molhoek, K.R., Shada, A.L., Smolkin, M., Chowbina, S., Papin, J., Brautigan, D.L., and Slingluff, C.L. Jr (2011). Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res. 21, 274-284.
17. Mulvihill, M.J., Cooke, A., Rosenfeld-Franklin, M. et al. (2009). Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153-1171.
18. Natarajan, K., and Berk, B.C. (2006). Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol. Biol. 332, 51-77.
19. Nogueira, C., Kim, K.H., Sung, H., Paraiso, K.H., Dannenberg, J.H., Bosenberg, M., Chin, L., and Kim, M. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 6222-6232.
20. Peavy, R.D., Chang, M.S., Sanders-Bush, E., and Conn, P.J. (2001). Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J. Neurosci. 21, 9619-9628.
21. Pollock, P.M., Cohen-Solal, K., Sood, R. et al. (2003). Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34, 108-112.
22. Prickett, T.D., Wei, X., Cardenas-Navia, I. et al. (2011). Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43, 1119-1126.
23. Sachdev, D., Hartell, J.S., Lee, A.V., Zhang, X., and Yee, D. (2004). A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J. Biol. Chem. 279, 5017-5024.
24. Satyamoorthy, K., Li, G., Vaidya, B., Patel, D., and Herlyn, M. (2001). Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 61, 7318-7324.
25. Schiffner, S., Chen, S., Becker, J.C., and Bosserhoff, A.K. (2012). Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases. Exp. Dermatol. 21, 786-788.
26. Shin, S.S., Martino, J.J., and Chen, S. (2008a). Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology 55, 396-402.
27. Shin, S.S., Namkoong, J., Wall, B.A., Gleason, R., Lee, H.J., and Chen, S. (2008b). Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res. 21, 368-378.
28. Shin, S.S., Wall, B.A., Goydos, J.S., and Chen, S. (2010). AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res. 23, 103-111.
29. Sitcheran, R., Comb, W.C., Cogswell, P.C., and Baldwin, A.S. (2008). Essential role for epidermal growth factor receptor in glutamate receptor signaling to NF-kappaB. Mol. Cell. Biol. 28, 5061-5070.
30. Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
31. Straussman, R., Morikawa, T., Shee, K. et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
32. Teh, J.L., and Chen, S. (2012). Glutamatergic signaling in cellular transformation. Pigment Cell Melanoma Res. 25, 331-342.
33. Tu, H., Xu, C., Zhang, W., Liu, Q., Rondard, P., Pin, J.P., and Liu, J. (2010). GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation. J. Neurosci. 30, 749-759.
34. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
35. Yip, D., Le, M.N., Chan, J.L., Lee, J.H., Mehnert, J.A., Yudd, A., Kempf, J., Shih, W.J., Chen, S., and Goydos, J.S. (2009). A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin. Cancer Res. 15, 3896-3902.
36. Zahradka, P., Litchie, B., Storie, B., and Helwer, G. (2004). Transactivation of the insulin-like growth factor-I receptor by angiotensin II mediates downstream signaling from the angiotensin II type 1 receptor to phosphatidylinositol 3-kinase. Endocrinology 145, 2978-2987.
37. Zhao, H., Desai, V., Wang, J., Epstein, D.M., Miglarese, M., and Buck, E. (2012). Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol. Cancer Ther. 11, 503-513.